When did obesity become a drug deficiency?

The mystery is not that metabolism responded to a dramatically altered environment. The mystery is why medicine became so comfortable treating that response without demonstrating comparable urgency about the environment that produced it.

Then came the drugs that actually worked

Obesity medicine has a long and sometimes uncomfortable pharmacological history. Earlier drugs frequently produced modest weight loss, troublesome adverse effects, or both. Several were eventually withdrawn because their risks became unacceptable. Against that background, modern incretin-based therapies represented a genuine therapeutic breakthrough. In the STEP 1 trial, adults with overweight or obesity who received once-weekly semaglutide 2.4 mg lost an average of 14.9 percent of their baseline body weight over 68 weeks, compared with 2.4 percent among those receiving placebo, with both groups receiving lifestyle intervention.[3] For nonsurgical obesity treatment, this was an extraordinary result.

Tirzepatide moved the numbers even further. In SURMOUNT-1, 2,539 adults with obesity or overweight and at least one weight-related complication, but without diabetes, were randomized to tirzepatide or placebo. At 72 weeks, average weight reductions were 15.0 percent, 19.5 percent, and 20.9 percent with the 5 mg, 10 mg, and 15 mg doses, respectively, compared with 3.1 percent with placebo.[4] Weight reductions exceeding 20 percent begin to approach territory historically associated with bariatric procedures rather than medication. For patients who have struggled unsuccessfully with obesity for years, it is easy to understand why these drugs can feel revolutionary.

More importantly, the story extends beyond the scale. In SELECT, more than 17,000 adults with preexisting cardiovascular disease and overweight or obesity, but without diabetes, were randomized to semaglutide or placebo. Major cardiovascular events occurred in 6.5 percent of patients receiving semaglutide and 8.0 percent receiving placebo, corresponding to a hazard ratio of 0.80.[5] Subsequent analysis also demonstrated a lower incidence of a prespecified composite kidney endpoint among patients receiving semaglutide.[13] Tirzepatide has produced substantial reductions in apnea-hypopnea index among patients with obesity and moderate-to-severe obstructive sleep apnea.[6] These findings make it impossible to dismiss the GLP-1 era as mere pharmaceutical vanity medicine.

Physicians should welcome effective therapies. A patient with severe obesity, cardiovascular disease, diabetes, sleep apnea, impaired mobility, or other obesity-related complications should not be denied a beneficial treatment because society has failed to solve the larger causes of obesity. We treat the patient who exists today, not the healthier society we wish existed. The mistake would be turning that entirely reasonable clinical principle into permission to stop asking the larger question.

What happens when the injection stops?

Perhaps the most revealing aspect of GLP-1 therapy appears when treatment ends. In the STEP 1 extension, participants who discontinued semaglutide regained approximately two-thirds of their previous weight loss during the following year, while many cardiometabolic improvements moved back toward baseline.[14] SURMOUNT-4 demonstrated a similar phenomenon with tirzepatide. After an initial 36-week period during which participants lost an average of 20.9 percent of their body weight, those randomized to discontinue tirzepatide and receive placebo regained substantial weight, whereas those who continued therapy maintained and further increased their weight reduction.[15]

The conventional interpretation is straightforward: obesity is a chronic relapsing disease, and chronic diseases frequently require chronic treatment. This argument has considerable logic. Blood pressure often rises when antihypertensive medications are stopped. LDL cholesterol generally rises after discontinuation of lipid-lowering therapy. Nobody claims that the recurrence of hypertension proves that antihypertensive drugs failed.

The 2026 American Diabetes Association Standards of Care therefore recommend continuing obesity pharmacotherapy beyond achievement of weight-loss goals when indicated for chronic therapy, noting that discontinuation often results in recurrent weight gain and reemergence of cardiometabolic risk factors.[16] The World Health Organization likewise now states that GLP-1 therapies may be used as long-term treatment for adults living with obesity. However, its recommendation is conditional and recognizes the need for comprehensive behavioral and lifestyle intervention.[17]

Yet, obesity differs from many chronic diseases in one important respect: its prevalence changed dramatically within a remarkably short historical period. That should make us cautious about letting "chronic disease" end the discussion. If the environment continually pushes human metabolism toward excess adiposity, and a drug successfully counteracts that pressure only while it is administered, lifelong pharmacotherapy may be entirely appropriate for some patients. But it should simultaneously intensify our interest in the pressure itself. Otherwise, we risk defining successful medicine as the indefinite pharmacological adaptation of human beings to an unhealthy environment.

Losing weight is not the same as losing fat

Another part of this conversation deserves more attention, particularly as these medications expand into older populations. Large reductions in body weight do not consist exclusively of adipose tissue. During weight loss, some lean tissue is generally lost as well, regardless of whether weight reduction occurs through caloric restriction, surgery, or pharmacotherapy. The relevant question is not whether lean mass changes, but how much is lost, in whom, and what the functional consequences may be.

A DXA substudy of SURMOUNT-1 found that participants receiving tirzepatide experienced a 21.3 percent reduction in body weight, accompanied by a 33.9 percent reduction in fat mass and a 10.9 percent reduction in lean mass. Approximately three-quarters of the lost weight was fat, and one-quarter was lean mass.[18] That is a far more nuanced finding than the popular claim that GLP-1 drugs "destroy muscle."

They do not. Body composition generally improves because more fat than lean tissue is lost proportionally. Nevertheless, lean tissue is biologically important, and its loss should not be treated as irrelevant simply because the scale is moving in the desired direction.